PMV Pharmaceuticals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PMV Pharmaceuticals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($77.74M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($58.71M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | ($68.96M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2022 | ($73.32M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($57.85M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($34.44M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($25.35M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($17.54M) | Mar 3, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($86.21M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($85.45M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | ($80.13M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2022 | ($77.04M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($58.29M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($34.94M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($26.64M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($18.89M) | Mar 3, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $69.88M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $58.53M | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | $55.89M | Mar 6, 2026 |
| FY2024 | Dec 31, 2022 | $51.99M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $36.49M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $23.93M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $20.76M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $13.85M | Mar 3, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($73.58M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($51.28M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | ($55.66M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2022 | ($63.76M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($46.57M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($32.74M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($22.07M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($15.18M) | Mar 3, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.0K | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $655.0K | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | $962.0K | Mar 6, 2026 |
| FY2024 | Dec 31, 2022 | $7.98M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $1.35M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $148.0K | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $109.0K | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $452.0K | Mar 3, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $116.56M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $191.29M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $252.15M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $270.31M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $331.57M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $365.53M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $103.03M | Mar 3, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.85M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $15.21M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $26.46M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $24.28M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $23.01M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $6.41M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $4.57M | Mar 3, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $104.71M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $176.08M | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | $225.69M | Mar 6, 2026 |
| FY2025 | Dec 31, 2022 | $246.03M | Mar 6, 2026 |
| FY2024 | Dec 31, 2021 | $308.56M | Mar 3, 2025 |
| FY2023 | Dec 31, 2020 | $359.12M | Feb 29, 2024 |
| FY2022 | Dec 31, 2019 | ($70.47M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2018 | ($46.14M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | ($29.73M) | Mar 3, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($446.45M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($368.71M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($310.00M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($241.04M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($167.73M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($109.88M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($75.44M) | Mar 3, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.98M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $40.88M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $37.71M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $108.30M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $172.47M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $361.42M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $73.28M | Mar 3, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Mar 6, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Mar 1, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Mar 6, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Mar 1, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 53.33M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | 51.94M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | 51.45M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | 45.77M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 45.43M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 44.78M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 3.05M | Mar 3, 2021 |